硼替佐米治疗难治性、复发性、多发性骨髓瘤的初步临床研究
详细信息-
摘要: 多发性骨髓瘤(MM)是发生在浆细胞的恶性克隆增殖性疾病,常见于中老年,约占所有血液系恶性肿瘤的10%.联合化疗甚至自体造血干细胞移植虽然提高了MM的缓解率并延长了患者的生存期,但直到最近MM仍然被认为是一种不能治愈的疾病.因此,难治/复发性MM 的治疗就成为血液病中需要解决的难题之一.2003年5月,一种新型的靶向治疗药物硼替佐米在美国被批准用于复发、难治性MM的治疗,取得了较好的效果.为了观察硼替佐米的疗效及不良反应,作者采用该药物治疗5例难治、复发性MM, 现将结果报道如下.
-
-
侯健, 傅卫军. 多发性骨髓瘤及其相关疾病 [M]. 上海:上海科学技术出版社, 2002.159. Bross P F, Kane R, Farrell A T. Approval summary for bortezomib for injection in the treatment of multiple myeloma [J]. Clinical Cancer Research, 2004, (15):3954.doi: 10.1158/1078-0432.CCR-03-0781. 张之南. 血液病诊断及疗效标准 [M]. 北京:科学出版社, 1998.373. Blade J, Samson D, Reece D. Criteria forevaluating disease responseand progression in patient swith multiple myeloma t reated by high dose therapy and haemopoietic stem cell t ransplantation. Myeloma Subcommitte for the EBMT [J]. British Journal of Haematology, 1998(5):1115. 瞿文, 邵宗鸿. 蛋白酶体抑制剂硼替佐米治疗血液恶性肿瘤的研究 [J]. 医学综述, 2007, (15):1181.doi: 10.3969/j.issn.1006-2084.2007.15.028. Richardson P G, Barlogie B, Berenson N J. A phase 2 study of bortezomib in replased, refractory myeloma [J]. New England Journal of Medicine, 2003, (26):2609.doi: 10.1056/NEJMoa030288. Richardson P G, Sonneveld P, Schuster M W. Bortezomib or highdose dexamethasone for relapsed multiple myeloma:A phase 3 randomized study (APEX) [J]. New England Journal of Medicine, 2005, (24):2487.doi: 10.1056/NEJMoa043445. Terpos E, Anagnostopoulos A, Kastritis E. The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide (VMDT) is an effective treatment for relapsed/refractory myeloma:Results of a phase Ⅱ clinical trial [J]. Blood, 2005.363.
计量
- 文章访问数: 119
- HTML全文浏览量: 18
- PDF下载量: 0
下载:
苏公网安备 32100302010246号
